TOP > 外国特許検索 > METHOD FOR DIAGNOSING ACUTE LUNG INJURY

METHOD FOR DIAGNOSING ACUTE LUNG INJURY

外国特許コード F120006837
整理番号 S2011-0359
掲載日 2012年9月5日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2012JP053174
国際公開番号 WO 2012108538
国際出願日 平成24年2月10日(2012.2.10)
国際公開日 平成24年8月16日(2012.8.16)
優先権データ
  • 特願2011-027679 (2011.2.10) JP
発明の名称 (英語) METHOD FOR DIAGNOSING ACUTE LUNG INJURY
発明の概要(英語) The present invention provides a useful diagnostic method and a useful diagnostic agent which are capable of diagnosing acute lung injury in clear distinction from chronic progressive interstitial pneumonia. The present invention specifically provides a method for determining whether a subject is suffering from acute lung injury or not, said method comprising quantitative determination of heat shock protein 47 in a biological sample derived from the subject.
従来技術、競合技術の概要(英語) BACKGROUND ART
Acute lung injury (Acute Lung Injury; also termed ALI) is, in a direct or indirect injury to the lungs of sepsis, diseases such as pneumonia, an injury or trauma, such as aspiration and/or malfunctions caused by an inflammatory disease of the lungs. Show nonspecific symptoms, dyspnea is the main symptom, sometimes with a cough or chest pain. Patients with acute lung injury, typically within 24-48 of the original injury or disease as indicated by the symptoms, leading to death in a serious case. Mortality rate is as high as 30-40%, to further increase the aging or Childhood.
Diagnosis of acute lung injury, which is basically performed by the clinical diagnosis. The clinical finding of acute lung injury, acute heart failure and lung infection is similar in both the clinical observations, a diagnosis and, in order to identify the cause, the patient any more ABG(Arterial Blood Gas; arterial blood gas test, the partial pressure of oxygen in the blood, CO2 partial pressure, measuring the pH and the like) and the chest of the subject to X-ray inspection thereof. However, acute lung injury is very rapidly, effective treatment has not been established, in a very poor prognosis of diseases. Pneumothorax or severe pulmonary complications such as bacterial infection which may develop. Therefore, in particular for early diagnosis is needed.
Recently, more convenient, in order to diagnose acute lung injury quickly as serum markers (sialic-carbohydrate antigen) KL-6, SP-D(Surfactant protein-D), SP-A(Surfactant protein-A) is such that the carrier can be used. However, these may be organized with idiopathic (cryptogenic organizing pneumonia pneumonia; COP), idiopathic normal interstitial (idiopathic usual interstitial pneumonia; idiopathic UIP), idiopathic nonspecific interstitial pneumonia (idiopathic nonspecific interstitial pneumonia; idiopathic NSIP), collagen-related normal interstitial (collagen vascular disease (CVD) -associated UIP), collagen-related nonspecific interstitial pneumonia (collagen vascular disease (CVD) -associated NSIP) and the like, chronic progressive interstitial known and are also markers, acute lung injury to clearly distinguish them for the diagnosis of, high specificity marker is not known.
Heat shock protein (HSP47) is 47, which has specificity for collagen and molecular chaperones, exists in the endoplasmic reticulum stress-induced heat shock has been known as a protein. HSP47 Expression, the expression of the collagen matrix from the conjugated, HSP47 in a variety of fibrotic diseases with the involvement is important has been pointed out (Patent Document 1-3, 8 and Non-Patent Document 6). In addition, acute lung injury in the role of the HSP47 phase of the fibrosis and the like are reported (non-patent document 1-3). Heretofore, fibrotic lung disease of the lung tissue topically to enhance HSP47 expression has been reported (Non-Patent Document 5 and 6), located within the endoplasmic reticulum HSP47 and does not leak to the outside of the cells which have been, with interstitial fibrosis (such as blood for example) in the extracellular in elevated HSP47 has not been considered. Reports are actually in idiopathic pulmonary fibrosis in the patient's serum and HSP47 healthy individuals with the same level, there is no increase in the clear (non-patent document 7). HSP47 Is, with a marked increase in acute lung injury and has been observed, acute lung injury and chronic progressive interstitial pneumonia can be clearly distinguished, is made to be useful biomarkers, it has not been known at all, which is not unexpected.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NAGASAKI UNIVERSITY
  • SAPPORO MEDICAL UNIVERSITY
  • 発明者(英語)
  • KAKUGAWA, Tomoyuki
  • YOKOTA, Shin-ichi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
上記の特許・技術に関心のある方は、下記問い合わせ先にご相談下さい。

PAGE TOP

close
close
close
close
close
close